The Effect of Cholesterol Reduction With Cholestyramine on Renal Function
Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large exist...
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2005-11, Vol.46 (5), p.812-819 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 819 |
|---|---|
| container_issue | 5 |
| container_start_page | 812 |
| container_title | American journal of kidney diseases |
| container_volume | 46 |
| creator | Kshirsagar, Abhijit V. Shoham, David A. Bang, Heejung Hogan, Susan L. Simpson, Ross J. Colindres, Romulo E. |
| description | Background:
Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo.
Methods:
A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups.
Results:
A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m
2 (0.007 mL/s/1.73 m
2;
P = 0.28) during a follow-up period of more than 8 years.
Conclusion:
Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals. |
| doi_str_mv | 10.1053/j.ajkd.2005.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68739720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638605012187</els_id><sourcerecordid>68739720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-39d4fa8f581a88e909b0e81592e15a7bec55a0b5bf25f9fd52da21c7c85fc94b3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWqt_wIPsRW-75qPZZMGLlFaFglAUjyGbndDU_dBkV_Dfm9oVb54GZp53mHkQuiA4I5izm22mt29VRjHmGZYZJvQATQinLM0lk4dogqmgac5kfoJOQ9hijAuW58fohOSUM0HxBD0-byBZWAumTzqbzDddDaEH39XJGqrB9K5rk1fXb35HX143roUkttfQ6jpZDu0PdYaOrK4DnI91il6Wi-f5Q7p6un-c361Sw-SsT1lRzayWlkuipYQCFyUGSXhBgXAtSjCca1zy0lJuC1txWmlKjDCSW1PMSjZF1_u97777GOJFqnHBQF3rFrohqFwKVsTfIkj3oPFdCB6seveu0f5LEax2AtVW7QSqnUCFpYoCY-hy3D6UDVR_kdFYBK5GQAeja-t1a1z44wQVghERuds9B9HFpwOvgnHQGqicj7JV1bn_7vgGlbuOfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68739720</pqid></control><display><type>article</type><title>The Effect of Cholesterol Reduction With Cholestyramine on Renal Function</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kshirsagar, Abhijit V. ; Shoham, David A. ; Bang, Heejung ; Hogan, Susan L. ; Simpson, Ross J. ; Colindres, Romulo E.</creator><creatorcontrib>Kshirsagar, Abhijit V. ; Shoham, David A. ; Bang, Heejung ; Hogan, Susan L. ; Simpson, Ross J. ; Colindres, Romulo E.</creatorcontrib><description>Background:
Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo.
Methods:
A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups.
Results:
A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m
2 (0.007 mL/s/1.73 m
2;
P = 0.28) during a follow-up period of more than 8 years.
Conclusion:
Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2005.08.012</identifier><identifier>PMID: 16253720</identifier><language>eng</language><publisher>Orlando, FL: Elsevier Inc</publisher><subject>Adult ; Anticholesteremic Agents - pharmacology ; Anticholesteremic Agents - therapeutic use ; Biological and medical sciences ; Cholesterol, Dietary - administration & dosage ; Cholestyramine Resin - pharmacology ; Cholestyramine Resin - therapeutic use ; Combined Modality Therapy ; Coronary Disease - epidemiology ; Coronary Disease - prevention & control ; Diet, Fat-Restricted ; Disorders of blood lipids. Hyperlipoproteinemia ; Double-Blind Method ; Glomerular Filtration Rate - drug effects ; Humans ; Hypercholesterolemia ; Hyperlipoproteinemia Type II - diet therapy ; Hyperlipoproteinemia Type II - drug therapy ; Hyperlipoproteinemia Type II - physiopathology ; Kidney - drug effects ; Kidney - physiopathology ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Nephrology. Urinary tract diseases ; randomized controlled trial ; renal function ; Risk Factors ; Treatment Failure</subject><ispartof>American journal of kidney diseases, 2005-11, Vol.46 (5), p.812-819</ispartof><rights>2005 National Kidney Foundation, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-39d4fa8f581a88e909b0e81592e15a7bec55a0b5bf25f9fd52da21c7c85fc94b3</citedby><cites>FETCH-LOGICAL-c384t-39d4fa8f581a88e909b0e81592e15a7bec55a0b5bf25f9fd52da21c7c85fc94b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638605012187$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17277317$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16253720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kshirsagar, Abhijit V.</creatorcontrib><creatorcontrib>Shoham, David A.</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Hogan, Susan L.</creatorcontrib><creatorcontrib>Simpson, Ross J.</creatorcontrib><creatorcontrib>Colindres, Romulo E.</creatorcontrib><title>The Effect of Cholesterol Reduction With Cholestyramine on Renal Function</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background:
Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo.
Methods:
A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups.
Results:
A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m
2 (0.007 mL/s/1.73 m
2;
P = 0.28) during a follow-up period of more than 8 years.
Conclusion:
Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.</description><subject>Adult</subject><subject>Anticholesteremic Agents - pharmacology</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cholesterol, Dietary - administration & dosage</subject><subject>Cholestyramine Resin - pharmacology</subject><subject>Cholestyramine Resin - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Coronary Disease - epidemiology</subject><subject>Coronary Disease - prevention & control</subject><subject>Diet, Fat-Restricted</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Double-Blind Method</subject><subject>Glomerular Filtration Rate - drug effects</subject><subject>Humans</subject><subject>Hypercholesterolemia</subject><subject>Hyperlipoproteinemia Type II - diet therapy</subject><subject>Hyperlipoproteinemia Type II - drug therapy</subject><subject>Hyperlipoproteinemia Type II - physiopathology</subject><subject>Kidney - drug effects</subject><subject>Kidney - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>randomized controlled trial</subject><subject>renal function</subject><subject>Risk Factors</subject><subject>Treatment Failure</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMoWqt_wIPsRW-75qPZZMGLlFaFglAUjyGbndDU_dBkV_Dfm9oVb54GZp53mHkQuiA4I5izm22mt29VRjHmGZYZJvQATQinLM0lk4dogqmgac5kfoJOQ9hijAuW58fohOSUM0HxBD0-byBZWAumTzqbzDddDaEH39XJGqrB9K5rk1fXb35HX143roUkttfQ6jpZDu0PdYaOrK4DnI91il6Wi-f5Q7p6un-c361Sw-SsT1lRzayWlkuipYQCFyUGSXhBgXAtSjCca1zy0lJuC1txWmlKjDCSW1PMSjZF1_u97777GOJFqnHBQF3rFrohqFwKVsTfIkj3oPFdCB6seveu0f5LEax2AtVW7QSqnUCFpYoCY-hy3D6UDVR_kdFYBK5GQAeja-t1a1z44wQVghERuds9B9HFpwOvgnHQGqicj7JV1bn_7vgGlbuOfw</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>Kshirsagar, Abhijit V.</creator><creator>Shoham, David A.</creator><creator>Bang, Heejung</creator><creator>Hogan, Susan L.</creator><creator>Simpson, Ross J.</creator><creator>Colindres, Romulo E.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>The Effect of Cholesterol Reduction With Cholestyramine on Renal Function</title><author>Kshirsagar, Abhijit V. ; Shoham, David A. ; Bang, Heejung ; Hogan, Susan L. ; Simpson, Ross J. ; Colindres, Romulo E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-39d4fa8f581a88e909b0e81592e15a7bec55a0b5bf25f9fd52da21c7c85fc94b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Anticholesteremic Agents - pharmacology</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cholesterol, Dietary - administration & dosage</topic><topic>Cholestyramine Resin - pharmacology</topic><topic>Cholestyramine Resin - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Coronary Disease - epidemiology</topic><topic>Coronary Disease - prevention & control</topic><topic>Diet, Fat-Restricted</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Double-Blind Method</topic><topic>Glomerular Filtration Rate - drug effects</topic><topic>Humans</topic><topic>Hypercholesterolemia</topic><topic>Hyperlipoproteinemia Type II - diet therapy</topic><topic>Hyperlipoproteinemia Type II - drug therapy</topic><topic>Hyperlipoproteinemia Type II - physiopathology</topic><topic>Kidney - drug effects</topic><topic>Kidney - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>randomized controlled trial</topic><topic>renal function</topic><topic>Risk Factors</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kshirsagar, Abhijit V.</creatorcontrib><creatorcontrib>Shoham, David A.</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Hogan, Susan L.</creatorcontrib><creatorcontrib>Simpson, Ross J.</creatorcontrib><creatorcontrib>Colindres, Romulo E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kshirsagar, Abhijit V.</au><au>Shoham, David A.</au><au>Bang, Heejung</au><au>Hogan, Susan L.</au><au>Simpson, Ross J.</au><au>Colindres, Romulo E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Cholesterol Reduction With Cholestyramine on Renal Function</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>46</volume><issue>5</issue><spage>812</spage><epage>819</epage><pages>812-819</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background:
Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo.
Methods:
A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups.
Results:
A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m
2 (0.007 mL/s/1.73 m
2;
P = 0.28) during a follow-up period of more than 8 years.
Conclusion:
Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.</abstract><cop>Orlando, FL</cop><pub>Elsevier Inc</pub><pmid>16253720</pmid><doi>10.1053/j.ajkd.2005.08.012</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-6386 |
| ispartof | American journal of kidney diseases, 2005-11, Vol.46 (5), p.812-819 |
| issn | 0272-6386 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68739720 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Anticholesteremic Agents - pharmacology Anticholesteremic Agents - therapeutic use Biological and medical sciences Cholesterol, Dietary - administration & dosage Cholestyramine Resin - pharmacology Cholestyramine Resin - therapeutic use Combined Modality Therapy Coronary Disease - epidemiology Coronary Disease - prevention & control Diet, Fat-Restricted Disorders of blood lipids. Hyperlipoproteinemia Double-Blind Method Glomerular Filtration Rate - drug effects Humans Hypercholesterolemia Hyperlipoproteinemia Type II - diet therapy Hyperlipoproteinemia Type II - drug therapy Hyperlipoproteinemia Type II - physiopathology Kidney - drug effects Kidney - physiopathology Male Medical sciences Metabolic diseases Middle Aged Nephrology. Urinary tract diseases randomized controlled trial renal function Risk Factors Treatment Failure |
| title | The Effect of Cholesterol Reduction With Cholestyramine on Renal Function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A17%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Cholesterol%20Reduction%20With%20Cholestyramine%20on%20Renal%20Function&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Kshirsagar,%20Abhijit%20V.&rft.date=2005-11-01&rft.volume=46&rft.issue=5&rft.spage=812&rft.epage=819&rft.pages=812-819&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2005.08.012&rft_dat=%3Cproquest_cross%3E68739720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68739720&rft_id=info:pmid/16253720&rft_els_id=S0272638605012187&rfr_iscdi=true |